Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy-Reference-Cited by-同舟云学术

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy

Published:2005-10 Issue:2 Volume:63 Page:456-462
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Lee Andrew K.,Levy Larry B.,Cheung Rex,Kuban Deborah

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference22 articles.

1. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation;Zagars;Cancer,1997

2. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate;Lawton;Int J Radiat Oncol Biol Phys,2001

3. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study);Bolla;Lancet,2002

4. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement;Granfors;J Urol,1998

5. Consensus statement;Int J Radiat Oncol Biol Phys,1997

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up;Journal of Clinical Oncology;2024-06-01

2. Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial;World Journal of Urology;2023-10-04

3. Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?;Clinical Genitourinary Cancer;2021-12

4. Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer;Advances in Radiation Oncology;2021-01

5. Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin;British Journal of Clinical Pharmacology;2019-04-03